Vaccine maker Seqirus announced plans to break ground early next year on a $600-million influenza vaccine manufacturing facility in Melbourne, Australia.
Capable of producing seasonal and pandemic flu vaccines, the plant will be the only cell-based influenza vaccine manufacturing facility in the Southern Hemisphere, says the company.